Tukysa (tucatinib) mixed with Herceptin (trastuzumab) and Perjeta (pertuzumab) prolonged progression-free survival as a frontline upkeep method in contrast with placebo plus...
The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent adjuvant remedy numerically elevated the...
